Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.

Annals of hematology - 1 Jul 2004

Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P

Abstract excerpt

Efforts have been undertaken to find an alternative approach to packed red cell transfusion (PRCT) in major beta-thalassemia. Augmentation of fetal hemoglobin (HbF) by hydroxyurea (HU) has been reported to be less effective in this condition as compared to sickle cell anemia due to molecular hete...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chelating Agents
Share to Deferoxamine
Share to Erythrocyte Transfusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erythropoiesis

Share to Facial Bones

Share to Globins

Share to Hydroxyurea

Share to Splenectomy

Source

Identifiers

PMID: 14722738
DOI: 10.1007/s00277-003-0836-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-14722738-2026-09-02.1. Manifest publication-graph-cohort-2026-09-02.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.PMID 14722738Read ↗

Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphismSemantic proximity Read ↗

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.Semantic proximity Read ↗

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.Semantic proximity Read ↗

Response to hydroxyurea therapy in beta-thalassemia.Semantic proximity Read ↗

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemicSemantic proximity Read ↗

Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the XmnI Polymorphism.Semantic proximity Read ↗

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.Semantic proximity Read ↗

Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.Semantic proximity Read ↗

Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.Semantic proximity Read ↗

A review of cis-trans interplay between DNA sequences 5' to the (G)gamma- and beta-globin genes among Hb F-Malta-I heterozygotes/homozygotes and beta-thalassemia homozygotes/compound heterozygotes, and the effects of hydroxyurea on the Hb F/F-erythrocyte; the need for large multicenter trials.Semantic proximity Read ↗

Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.Semantic proximity Read ↗

The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.